Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Resolving the signal-to-noise ratio challenge for precision liquid biopsy and early solid tumor surveillance

Objetivo

bio.SECRET introduces a fundamentally new liquid-biopsy approach for early detection and monitoring of solid-tumour recurrence. Existing solutions - imaging, serum biomarkers and first-generation liquid biopsies (ctDNA, exosomes) - are limited by low sensitivity, high variability and delayed detection, leaving a critical clinical gap in identifying recurrence and minimal residual disease at an early, actionable stage.
bio.SECRET directly overcomes these limitations by analysing the tumour secretome, the enriched mixture of molecules actively released by cancer cells. This upstream, tumour-centric strategy resolves the intrinsic signal-to-noise problem in plasma and enables the detection of low-abundance, biologically relevant biomarkers that conventional assays cannot capture. Pre-clinical data show a 4.9× increase in sensitivity, 99% reduction in plasma-protein interference, and identification of 1,300+ novel proteins, demonstrating clear technological superiority.
The project will advance the platform from TRL 4 to TRL 6 through: (i) optimisation and standardisation of the secretome-generation workflow using 150 patient-derived samples; (ii) identification and analytical validation of a secretome-derived biomarker panel for breast-cancer recurrence; and (iii) development of the first bio.SECRET Monitor™ – Breast multiplex immunoassay prototype, benchmarked against CA15.3 and CEA.
In parallel, the project will establish full investment and market readiness. Activities include: securing IP protection (priority patent filing and FTO analysis), developing CE-IVDR and ISO 13485 roadmaps, validating the value proposition with clinicians and diagnostic-lab users, and defining a clear commercial pathway. The dual strategy combining licensing of the discovery platform and biomarker panels to diagnostic and pharmaceutical partners (early revenues), and commercialisation of bio.SECRET Monitor™ diagnostic kits for clinical deployment, starting with breast cancer.

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-CSA - HORIZON Coordination and Support Actions

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) HORIZON-WIDERA-2025-02

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

ITINERANTSENSOR - LDA
Aportación neta de la UEn
€ 348 802,57
Dirección
R. 25, 175, 5dir
4500-281 ESPINHO
Portugal
Pyme
Sí
Región
Continente Norte Área Metropolitana do Porto
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
Sin datos